Irwin, Nigel

A novel glucagon-like peptide-1 (GLP-1)/Glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice

Gault, V. A., Bhat, V. K., Irwin, N., & Flatt, P. R. (2013) · Journal of Biological Chemistry

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 123

N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity

Green, B., Mooney, M., Gault, V., Irwin, N., Bailey, C., Harriott, P., Greer, B., O'Harte, F., & Flatt, P. (2004) · Journal of Endocrinology

Diabetes Treatment and ManagementChemical Synthesis and Analysis

Cited by 57

A novel acylated form of (d-Ala2)GIP with improved antidiabetic potential, lacking effect on body fat stores

Martin, C. M. A., Irwin, N., Flatt, P. R., & Gault, V. A. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 53

Novel Glucagon-Like Peptide-1 (GLP-1) Analog (Val8)GLP-1 Results in Significant Improvements of Glucose Tolerance and Pancreatic β-Cell Function after 3-Week Daily Administration in Obese Diabetic (ob/ob) Mice

Green, B. D., Lavery, K. S., Irwin, N., O’Harte, F. P. M., Harriott, P., Greer, B., Bailey, C. J., & Flatt, P. R. (2006) · The Journal of Pharmacology and Experimental Therapeutics

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 49

Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes

Lafferty, R. A., Flatt, P. R., & Irwin, N. (2021) · Current Opinion in Endocrinology, Diabetes & Obesity

Pancreatic function and diabetesNeuropeptides and Animal Physiology

Cited by 42

Enteroendocrine hormone mimetics for the treatment of obesity and diabetes

Irwin, N., & Flatt, P. R. (2013) · Current Opinion in Pharmacology

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 41

Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline

Irwin, N., Flatt, P. R., Patterson, S., & Green, B. D. (2010) · European Journal of Pharmacology

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 38

Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes

Irwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides

Adipokines, Inflammation, and Metabolic DiseasesRegulation of Appetite and Obesity

Cited by 27